Veeva Systems has underperformed the S&P 500 despite strong fundamentals and improving profitability. VEEV's revenue grew 16% year-over-year, gross profit rose to the mid-70s, and cash generation ...

Veeva: S&P 500 Inclusion Lifts Shares, and We See More Upside; Maintaining $287 Fair Value Estimate ...

PLEASANTON, Calif., May 27, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Falcon, an agentic platform and standard agents for life sciences' major drug development processes.

Fives ProSim, a subsidiary of the Fives Group and an expert in industrial process simulation and optimization, announces the release of ProSimPlus Python API. This new solution enables users to run ...

For years, Veeva's commercial software sat on top of Salesforce's (CRM-0.05%) infrastructure. While this enabled rapid scaling, it limited Veeva's control over its technical destiny and required ...

Veeva Systems Inc. is upgraded to a Buy as valuation resets after a 30% YTD decline, despite continued strong fundamentals. VEEV’s specialized, regulated software for life sciences makes it resilient ...

Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the ...

Veeva Systems acquired Ostro, a platform that offers an artificial intelligence-driven chatbot for patients and doctors, in a deal valued at $100 million. The life sciences software and data company ...

Veeva Systems Inc. (NYSE:VEEV) is among the 20 Best Investments in 2026. The fifth stock on our list of best investment stocks is Veeva Systems Inc. (NYSE:VEEV). TheFly reported on February 20 that ...

Earnings announcements are one of the few scheduled events that consistently move markets. Prices react not just to the reported numbers, but to how those numbers compare with expectations. A small ...

Markets respond to information faster than anything else, and most of that information begins with a headline. An earnings update, a regulatory note, a product issue, even a short line from an analyst ...